MS patient characteristics and healthcare resource utilization from administrative databases: real-world evidence from Alberta, Canada
Author(s): ,
B Gerber
Affiliations:
Medlior Health Outcomes Research Ltd.
,
T Cowling
Affiliations:
Medlior Health Outcomes Research Ltd
,
G Chen
Affiliations:
University of Calgary
,
M Yeung
Affiliations:
Multiple Sclerosis Clinic, University of Calgary, Calgary, AB
,
P Duquette
Affiliations:
Notre Dame Hospital, Université de Montréal, Montreal
,
R Schecter
Affiliations:
Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
P Haddad
Affiliations:
Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
ECTRIMS Online Library. Duquette P. 09/14/16; 145644; EP1549
Pierre Duquette
Pierre Duquette
Contributions
Abstract

Abstract: EP1549

Type: ePoster

Abstract Category: Therapy - disease modifying - Others

Objectives: Alberta has one of the highest rates of multiple sclerosis (MS) in the world with a prevalence of 1:400. This study"s objective is to determine the real-world impact of adherence to MS therapy on healthcare resource utilization outcomes from administrative data captured by the Alberta health system.

Methods: The patient cohort consisted of individuals who met the MS Case Definition: ≥1 inpatient record or ≥5 practitioner claims within 2 years. The study index disease-modifying therapy (DMT) was defined as the first claim for a DMT during the observation period (1April2011 to 31March2014). A preliminary analysis on the cohort demographics and clinical characteristics has been conducted. Analyses on the impact of adherence to DMT on healthcare resource utilization will be performed.

Results: A total of 2864 MS patients were identified with a DMT claim between 1April2011 to 31March2014. The population comprised of 74% females and 26% males. The most common age category was 35-55 years of age (62%), followed by < 35 (25%), 55-65 (12%) and >65 (1.5%) years of age. The highest proportions of patients were from Calgary (37%) and Edmonton (34%) followed by the Central zone (13%), North zone (9%) and South zone (7%). The most common comorbidities included: depression (31%), anxiety (18%) and hypertension (10%) with < 5% of the cohort identified as having each of the following conditions: chronic lung disease, hyperlipidemia, bipolar disorder, diabetes, cardiovascular disease, ischemic stroke, ischemic heart disease and epilepsy.

Conclusions: The demographics and clinical characteristics of the study population aligns with the description of patients from other MS administrative database research in Canada. Further analysis of the impact of adherence to DMTs on healthcare resource utilization will be conducted to inform the health system in Alberta.

Disclosure: Funding was provided by Novartis Pharmaceuticals Canada Inc.

Brittany Gerber - is employed by Medlior Health Outcomes Research Ltd. which received funding for the study from Novartis Pharmaceuticals Canada Inc.

Tara Cowling - is employed by Medlior Health Outcomes Research Ltd. which received funding for the study from Novartis Pharmaceuticals Canada Inc.

Guanmin Chen - is a consultant for Medlior Health Outcomes Research Ltd. which received funding for the study from Novartis Pharmaceuticals Canada Inc. He has also received research funding from the Canadian Institutes for Health Research (CIHR).

Michael Yeung - has received consultation fees from EMD Serono, Genzyme and Novartis, the Canadian Agency for Drugs and Technologies in Health (CADTH)/Health Canada, and research support from Biogen-Idec, Genzyme, Hoffmann-La Roche, Novartis, and Teva Canada Innovation.

Pierre Duquette - has received honoraria for advisory boards, for CMEs from Novartis, Biogen-Idec, Genzyme, EMD Serono and Teva Neurosience. He has taken part in Investigator-initiated trials funded by Novartis, Biogen-Idec, Genzyme and EMD Serono and has received funding from peer-reviewed agencies such as the Canadian Institutes for Health Research (CIHR) and the MS Society of Canada.

Robyn Schecter - is an employee of Novartis Pharmaceuticals Canada Inc.

Paola Haddad - is an employee of Novartis Pharmaceuticals Canada Inc.

Abstract: EP1549

Type: ePoster

Abstract Category: Therapy - disease modifying - Others

Objectives: Alberta has one of the highest rates of multiple sclerosis (MS) in the world with a prevalence of 1:400. This study"s objective is to determine the real-world impact of adherence to MS therapy on healthcare resource utilization outcomes from administrative data captured by the Alberta health system.

Methods: The patient cohort consisted of individuals who met the MS Case Definition: ≥1 inpatient record or ≥5 practitioner claims within 2 years. The study index disease-modifying therapy (DMT) was defined as the first claim for a DMT during the observation period (1April2011 to 31March2014). A preliminary analysis on the cohort demographics and clinical characteristics has been conducted. Analyses on the impact of adherence to DMT on healthcare resource utilization will be performed.

Results: A total of 2864 MS patients were identified with a DMT claim between 1April2011 to 31March2014. The population comprised of 74% females and 26% males. The most common age category was 35-55 years of age (62%), followed by < 35 (25%), 55-65 (12%) and >65 (1.5%) years of age. The highest proportions of patients were from Calgary (37%) and Edmonton (34%) followed by the Central zone (13%), North zone (9%) and South zone (7%). The most common comorbidities included: depression (31%), anxiety (18%) and hypertension (10%) with < 5% of the cohort identified as having each of the following conditions: chronic lung disease, hyperlipidemia, bipolar disorder, diabetes, cardiovascular disease, ischemic stroke, ischemic heart disease and epilepsy.

Conclusions: The demographics and clinical characteristics of the study population aligns with the description of patients from other MS administrative database research in Canada. Further analysis of the impact of adherence to DMTs on healthcare resource utilization will be conducted to inform the health system in Alberta.

Disclosure: Funding was provided by Novartis Pharmaceuticals Canada Inc.

Brittany Gerber - is employed by Medlior Health Outcomes Research Ltd. which received funding for the study from Novartis Pharmaceuticals Canada Inc.

Tara Cowling - is employed by Medlior Health Outcomes Research Ltd. which received funding for the study from Novartis Pharmaceuticals Canada Inc.

Guanmin Chen - is a consultant for Medlior Health Outcomes Research Ltd. which received funding for the study from Novartis Pharmaceuticals Canada Inc. He has also received research funding from the Canadian Institutes for Health Research (CIHR).

Michael Yeung - has received consultation fees from EMD Serono, Genzyme and Novartis, the Canadian Agency for Drugs and Technologies in Health (CADTH)/Health Canada, and research support from Biogen-Idec, Genzyme, Hoffmann-La Roche, Novartis, and Teva Canada Innovation.

Pierre Duquette - has received honoraria for advisory boards, for CMEs from Novartis, Biogen-Idec, Genzyme, EMD Serono and Teva Neurosience. He has taken part in Investigator-initiated trials funded by Novartis, Biogen-Idec, Genzyme and EMD Serono and has received funding from peer-reviewed agencies such as the Canadian Institutes for Health Research (CIHR) and the MS Society of Canada.

Robyn Schecter - is an employee of Novartis Pharmaceuticals Canada Inc.

Paola Haddad - is an employee of Novartis Pharmaceuticals Canada Inc.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies